If you had to sum up the 2016 MPO Summit in one word, it would be “relationships.” That’s the theme that runs through many of the sessions planned for this year’s event.
First, and perhaps foremost, visitors will enjoy the relationship building that will happen at the actual event. The opportunity exists to speak directly with the editorial team and the
publisher (ignoring for a moment that we’re always open to
your e-mails, calls, tweets, Facebook messages, or some other
preferred form of communication). There will be plenty of time
to build a relationship with a representative from one of the
20-plus sponsors who will be ready to discuss potential ways
in which they can resolve a challenge or provide a much needed service. The opportunity will exist to even develop a relationship with a local contact from the Austin or Texas region
tied to a city, state, or life science organization. All of these
entities have been lending valuable support to the event planning and organization, and many will be present to speak with
those interested in exploring the region, perhaps as a potential
location for a new facility.
“Austin is rapidly gaining momentum in the biotech,
medtech, and life science industries. With BioAustin’s networking, education, and collaboration events working to
transform the excellence seen in entrepreneurial internet
startups to the life sciences; recent IPOs (Mirna Therapeutics
and Aeglea Biotherapeutics); a growing medtech focus at the
annual international SXSW conference; and the formation of
the first medical school in nearly 50 years from the ground up
at a top tier research university (Dell Medical School, University of Texas at Austin), we look forward to becoming the recognized leader of biotechnology innovation in the next several
years,” stated Scott Collins, Ph.D., board member of BioAustin.
Additionally, on hand will be the superb line-up of speakers, many of whom will not only have the theme of relationships as part of their presentation, but will remain at the event
for a period of time as their schedule permits for attendees to
speak with about their specific concerns.
Regarding those sessions, as mentioned previously, the
theme of relationships and its importance between several
parties within medtech will run throughout a number of sessions. One such focus will be the relationship between OEMs
and their suppliers. One of the panel discussions will look at
this specifically. Four executives—two from the OEM side and
two from the supply side—will sit down with MPO’s publisher,
serving as moderator, to address a variety of issues and challenges. Topics will include how OEMs can assess the value
they gain from suppliers at the price paid, when to buy (or
outsource) and when to build (or bring in-house), and the
transformation from supplier to true development partner.
Another session will look specifically at the liability risk that
can emanate from an OEM’s supply chain.
Another relationship focus is that of the OEM and U.S. Food
and Drug Administration (FDA). Three afternoon sessions on
the first day are focused on regulatory issues, with two maintaining, in part, the relationship theme. One session looks at
strategies for staying abreast of the changes that are occurring
at the FDA. While not every change or guidance issued impacts
every device maker, it is paramount that OEMs ensure they are
aware of those that do affect their business and the products
they produce. Another session will critically examine the FDA
and its oversight of the industry. Does this agency truly have the
public’s best interests in mind, or is it overbearing to the point
that medtech innovation suffers? Further, how might the future
improve this sometimes turbulent situation?
The sessions on that first day should hopefully give attendees plenty to discuss during the evening reception scheduled
immediately after the last speaker wraps up. The reception
offers yet another opportunity for attendees, speakers, and
sponsor representatives to network and explore potential
Rounding out the conference schedule on the first day is a
“State of the Industry” panel discussion with several industry consultants and a representative from the Medical Device
Manufacturers Association. MPO’s editor will moderate what
should be a lively discussion, with topics that include a look
at the upcoming presidential election and its impact on the
medtech and healthcare industries, predictions on the fate of
the device excise tax, the reported improvement of FDA review
times, and trends in consolidation.
Following up this packed, “relationship-centric” agenda,
the second day is more of a look at innovation. With two single
speaker sessions and a panel discussion, Day 2 will highlight
innovation that’s happening in early development. While one
session highlights the university and R&D occurring in that
environment, another session specifically focuses on the challenges of developing point-of-care technology for the home.
Finally, a panel discussion will examine the influence of the
tech industry on today’s medical device development.
The 2016 MPO Summit will maintain a focus on key concepts critical to ensuring the success of today’s device makers.
From providing a platform for building stronger relationships
through networking opportunities and education to providing a unique view of technology innovation, this event will be
a can’t miss for medtech executives. The team at MPO looks
forward to meeting with you in person at the event and hearing your own impression of the Summit, while furthering your
relationship with us.
Get further details on the conference sessions and find out
more about the 2016 MPO Summit at www.mposummit.com. ❖
MPO Summit 2016 Preview
The 2016 MPO Summit will maintain a focus on key concepts
critical to ensuring the success of today’s device makers.